Korro Bio, Inc.
KRRO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001703647
In the last 90 days, Korro Bio, Inc. insiders filed 1 open-market purchase and 8 sales; 106 institutions reported holding it in 13F filings for Q2 2026, worth $190.1M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Korro Bio, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 55 | 50 | −5 |
| Shares | 7.89M | 7.40M | −488.6K (−6.2%) |
| Value | $14.1M | $28.3M | +$14.2M (+100.7%) |
New holders (4)
Institutions that held Korro Bio, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Duncker Streett & Co Inc | 14,355 | $55.3K | 0.01% |
| Belpointe Asset Management LLC | 9,675 | $37.2K | 0.00% |
| Simplex Trading, LLC | 7,802 | $30.0K | 0.00% |
| Group One Trading, L.P. | 157 | $604 | 0.00% |
Sold out (9)
Institutions that held Korro Bio, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Qube Research & Technologies Ltd | 24,952 | $45.0K |
| Cubist Systematic Strategies, LLC | 12,887 | $23.0K |
| Balyasny Asset Management LLC | 11,731 | $21.0K |
| LMR Partners LLP | 11,538 | $21.0K |
| Verition Fund Management LLC | 10,267 | $18.0K |
| Citigroup Inc | 420 | $1.00K |
| China Universal Asset Management Co., Ltd. | 330 | $1.00K |
| Credit Suisse AG | 89 | $0 |
| Daiwa Securities Group Inc. | 63 | $0 |